Clementia Receives Fast-Track Designation from FDA for Palovarotene
MONTREAL, Dec. 1, 2014
The IFOPA is pleased to share news that Clementia Pharmaceuticals received Fast Track Designation for palovarotene for the treatment of FOP. This designation does not impact the clinical trial that is taking place for our FOP community. To download and read the entire announcement please click on Clementia Receives Fast-Track Designation from FDA for Palovarotene.
No comments:
Post a Comment